Treatment of rheumatoid joint inflammation with intrasynovial triamcinolone hexacetonide.
OBJECTIVE
To determine the effectiveness of intrasynovial triamcinolone hexacetonide coupled with joint rest (3 weeks upper extremity; 6 weeks lower extremity) in the treatment of joint and tendon sheath inflammation in patients with seropositive rheumatoid arthritis (RA).


METHODS
The medical records of 169 patients with seropositive RA treated by a single rheumatologist for at least one year between 1974 and 1992 were abstracted.


RESULTS
Nine hundred fifty-six injections were given to 140 patients; approximately 75% of injected synovial structures remained in remission during a mean followup 7 years; 218 injections were given into previously treated structures. The injection rate was about 2 per patient in the first year, half of which were given at the time of the first visit. The rate then approximated 0.6 injections per patient-year for the next 15 years. Joints in the right upper extremity were injected significantly (p = 0.01) more frequently than those on the left.


CONCLUSIONS
Intrasynovial triamcinolone hexacetonide followed by rest is a very useful adjunctive modality in the treatment of seropositive rheumatoid arthritis.
Department of Medicine, Medical College of Wisconsin, Milwaukee 53226, USA.
D J
DJ
McCarty
J G
JG
Harman
J L
JL
Grassanovich
C
C
Qian
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001510:Bed Rest; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D007270:Injections, Intra-Articular; D012074:Remission Induction; D016896:Treatment Outcome; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
D000893:Anti-Inflammatory Agents; D014222:Triamcinolone Acetonide; C005900:triamcinolone hexacetonide